Cargando…

Novel in Vitro Model for Keratoconus Disease

Keratoconus is a disease where the cornea becomes cone-like due to structural thinning and ultimately leads to compromised corneal integrity and loss of vision. Currently, the therapeutic options are corrective lenses for early stages and surgery for advanced cases with no in vitro model available....

Descripción completa

Detalles Bibliográficos
Autores principales: Karamichos, Dimitrios, Zareian, Ramin, Guo, Xiaoqing, Hutcheon, Audrey E.K., Ruberti, Jeffrey W., Zieske, James D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3719435/
https://www.ncbi.nlm.nih.gov/pubmed/23888249
http://dx.doi.org/10.3390/jfb3040760
_version_ 1782277916105637888
author Karamichos, Dimitrios
Zareian, Ramin
Guo, Xiaoqing
Hutcheon, Audrey E.K.
Ruberti, Jeffrey W.
Zieske, James D.
author_facet Karamichos, Dimitrios
Zareian, Ramin
Guo, Xiaoqing
Hutcheon, Audrey E.K.
Ruberti, Jeffrey W.
Zieske, James D.
author_sort Karamichos, Dimitrios
collection PubMed
description Keratoconus is a disease where the cornea becomes cone-like due to structural thinning and ultimately leads to compromised corneal integrity and loss of vision. Currently, the therapeutic options are corrective lenses for early stages and surgery for advanced cases with no in vitro model available. In this study, we used human corneal fibroblasts (HCFs) and compared them to human Keratoconus fibroblasts (HKCs) cultured in a 3-dimensional (3D) model, in order to compare the expression and secretion of specific extracellular matrix (ECM) components. For four weeks, the cells were stimulated with a stable Vitamin C (VitC) derivative ± TGF-β1 or TGF-β3 (T1 and T3, respectively). After four weeks, HKCs stimulated with T1 and T3 were significantly thicker compared with Control (VitC only); however, HCF constructs were significantly thicker than HKCs under all conditions. Both cell types secreted copious amounts of type I and V collagens in their assembled, aligned collagen fibrils, which increased in the degree of alignment upon T3 stimulation. In contrast, only HKCs expressed high levels of corneal scarring markers, such as type III collagen, which was dramatically reduced with T3. HKCs expressed α-smooth muscle actin (SMA) under all conditions in contrast to HCFs, where T3 minimized SMA expression. Fast Fourier transform (FFT) data indicated that HKCs were more aligned when compared to HCFs, independent of treatments; however, HKC’s ECM showed the least degree of rotation. HKCs also secreted the most aligned type I collagen under T3 treatment, when compared to any condition and cell type. Overall, our model for Keratoconus disease studies is the first 3D in vitro tissue engineered model that can mimic the Keratoconus disease in vivo and may be a breakthrough in efforts to understand the progression of this disease.
format Online
Article
Text
id pubmed-3719435
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-37194352013-07-23 Novel in Vitro Model for Keratoconus Disease Karamichos, Dimitrios Zareian, Ramin Guo, Xiaoqing Hutcheon, Audrey E.K. Ruberti, Jeffrey W. Zieske, James D. J Funct Biomater Article Keratoconus is a disease where the cornea becomes cone-like due to structural thinning and ultimately leads to compromised corneal integrity and loss of vision. Currently, the therapeutic options are corrective lenses for early stages and surgery for advanced cases with no in vitro model available. In this study, we used human corneal fibroblasts (HCFs) and compared them to human Keratoconus fibroblasts (HKCs) cultured in a 3-dimensional (3D) model, in order to compare the expression and secretion of specific extracellular matrix (ECM) components. For four weeks, the cells were stimulated with a stable Vitamin C (VitC) derivative ± TGF-β1 or TGF-β3 (T1 and T3, respectively). After four weeks, HKCs stimulated with T1 and T3 were significantly thicker compared with Control (VitC only); however, HCF constructs were significantly thicker than HKCs under all conditions. Both cell types secreted copious amounts of type I and V collagens in their assembled, aligned collagen fibrils, which increased in the degree of alignment upon T3 stimulation. In contrast, only HKCs expressed high levels of corneal scarring markers, such as type III collagen, which was dramatically reduced with T3. HKCs expressed α-smooth muscle actin (SMA) under all conditions in contrast to HCFs, where T3 minimized SMA expression. Fast Fourier transform (FFT) data indicated that HKCs were more aligned when compared to HCFs, independent of treatments; however, HKC’s ECM showed the least degree of rotation. HKCs also secreted the most aligned type I collagen under T3 treatment, when compared to any condition and cell type. Overall, our model for Keratoconus disease studies is the first 3D in vitro tissue engineered model that can mimic the Keratoconus disease in vivo and may be a breakthrough in efforts to understand the progression of this disease. MDPI 2012-11-13 /pmc/articles/PMC3719435/ /pubmed/23888249 http://dx.doi.org/10.3390/jfb3040760 Text en © 2012 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Karamichos, Dimitrios
Zareian, Ramin
Guo, Xiaoqing
Hutcheon, Audrey E.K.
Ruberti, Jeffrey W.
Zieske, James D.
Novel in Vitro Model for Keratoconus Disease
title Novel in Vitro Model for Keratoconus Disease
title_full Novel in Vitro Model for Keratoconus Disease
title_fullStr Novel in Vitro Model for Keratoconus Disease
title_full_unstemmed Novel in Vitro Model for Keratoconus Disease
title_short Novel in Vitro Model for Keratoconus Disease
title_sort novel in vitro model for keratoconus disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3719435/
https://www.ncbi.nlm.nih.gov/pubmed/23888249
http://dx.doi.org/10.3390/jfb3040760
work_keys_str_mv AT karamichosdimitrios novelinvitromodelforkeratoconusdisease
AT zareianramin novelinvitromodelforkeratoconusdisease
AT guoxiaoqing novelinvitromodelforkeratoconusdisease
AT hutcheonaudreyek novelinvitromodelforkeratoconusdisease
AT rubertijeffreyw novelinvitromodelforkeratoconusdisease
AT zieskejamesd novelinvitromodelforkeratoconusdisease